Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

The role of chromatin modifier protein hDaxx and its interaction partners in intrinsic resistance to virus infection.

Objective

Herpes simplex virus (HSV) types 1 and 2 are significant and common human pathogens. Although most infections are mild, they cause one of the most common sexually transmitted diseases, infections in the eye can lead to blindness, active genital herpes necessitates caesarean delivery, and herpes encephalitis is usually fatal. Current anti-HSV drugs based on acyclovir are effective, but there will be a future need for alternative antiviral treatments. After a primary infection, HSV establishes a lifelong latent state from which it reactivates periodically, leading to recurring disease. Latent viral genomes are in a heterochromatin-like state in which transcription of almost all viral genes is repressed. Reactivation involves de-repression of viral gene transcription. Understanding the mechanisms by which HSV can establish, maintain and reactivate from latent infections may reveal avenues for the development of novel therapies. Cells express certain proteins that confer intrinsic resistance to DNA virus infections by repressing viral transcription. In turn, viruses encode proteins that combat this repression and thus increase viral gene expression. The interplay between these pathways determines whether HSV initiates a lytic or quiescent infection and is likely to be important in the regulation of latency. This project proposes to study hDaxx, a cellular protein that contributes to intrinsic antiviral resistance by repressing viral gene expression at the earliest stages of infection. Using novel technologies to deplete cells of endogenous hDaxx, then to reintroduce expression of normal and mutant forms of the protein, this project will define the sequence motifs and interaction partners of hDaxx that are required for its antiviral activity. A detailed understanding of the molecular mechanisms involved in hDaxx mediated repression, and the way in which its activity is counteracted by viral regulators, may reveal novel avenues for the treatment of herpesvirus infections.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-PEOPLE-2009-IEF
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MC-IEF - Intra-European Fellowships (IEF)

Coordinator

MEDICAL RESEARCH COUNCIL
EU contribution
€ 172 240,80
Address
20 Park Crescent
W1B 1AL LONDON
United Kingdom

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0